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Abstract 
Previously, the Rab-GTPase activating proteins TBC1D1 and TBC1D4 (AS160) were shown 
to regulate GLUT4 translocation in response to activation of AKT and AMP-dependent 
kinase. However, knockout mice lacking either Tbc1d1 or Tbc1d4 displayed only partially 
impaired insulin-stimulated glucose uptake in fat and muscle tissue. The aim of this study was 
to determine the impact of the combined inactivation of Tbc1d1 and Tbc1d4 on glucose 
metabolism in double-deficient (D1/4KO) mice. D1/4KO mice displayed normal fasting 
glucose levels but had reduced tolerance to intraperitoneally administered glucose, insulin and 
AICAR, respectively. D1/4KO mice showed reduced respiratory quotient, indicating 
increased use of lipids as fuel. Consistently, D1/4KO mice showed elevated fatty acid 
oxidation in isolated skeletal muscle whereas insulin-stimulated glucose uptake in muscle and 
adipose cells was almost completely abolished. In skeletal muscle and white adipose tissue, 
the abundance of GLUT4 protein but not GLUT4 mRNA was substantially reduced. Cell 
surface labeling of glucose transporters indicated that RabGAP-deficiency impairs basal retention 
of GLUT4 in the basal state. Our results show that TBC1D1 and TBC1D4 together play 
essential roles in insulin-stimulated glucose uptake and substrate preference in skeletal muscle 
and adipose cells. (187 words) 
 
Introduction 
In skeletal muscle and adipose cells, insulin stimulation leads to a rapid and reversible 
redistribution of GLUT4 glucose transporters from intracellular vesicles to the cell surface (1; 
2).  The two related Rab–GTPase-activating proteins TBC1D1 and TBC1D4 (AS160) are 
phosphorylated in response to insulin, AMP-activated protein kinase (AMPK), and 
exercise/muscle contraction and have been implicated in playing important roles in regulating 
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the translocation of GLUT4 (3-9). By positional cloning, we previously identified a naturally 
occurring loss-of-function mutation in Tbc1d1 as an obesity suppressor in the lean, diabetes-
resistant SJL mouse strain (10). In humans, mutations in TBC1D4 (R363X) and TBC1D1 
(R125W) have been linked to severe postprandial hyperinsulinemia and obesity, respectively 
(11-13). TBC1D4 is found mainly in the heart, adipose tissue and oxidative muscle fibers 
whereas TBC1D1 is predominantly expressed in glycolytic skeletal muscle and is nearly 
absent from fat tissue (10; 14; 15). Both TBC1D1 and TBC1D4 display a similar domain 
architecture that includes two N-terminal phosphotyrosine-binding (PTB) domains and a Rab-
GTPase activating (GAP) domain. The latter is believed to control the activation state of 
RabGTPases by converting them from the active, GTP-bound state into the inactive GDP-
bound state. Several lines of evidence suggest that the GAP domains in TBC1D1 and 
TBC1D4 directly regulate the activity of an overlapping set of Rab-GTPases, thereby 
controlling the subcellular targeting and transport activity of GLUT4 (7). So far, Rab2, 
Rab8b, Rab10 and Rab14 have been identified as substrates for recombinant GAP domains of 
TBC1D1 and TBC1D4 in vitro (4; 16), but the significance of these findings for GLUT4 
translocation in adipose and muscle cells in vivo remains to be further investigated.  
Moreover, the PTB domains may also be involved in signaling of TBC1D1/TBC1D4 (17-19). 
Previous studies in isolated L6 muscle cells and 3L3-L1 adipocytes have demonstrated that 
ablation of either Tbc1d1 or Tbc1d4, or overexpression of mutated proteins resulted in 
reduced insulin-stimulated translocation of GLUT4 (20-22). However, knockout mice lacking 
either Tbc1d1 (15; 23) or Tbc1d4 (14; 24) displayed only tissue-specific impairments of 
insulin-stimulated glucose uptake and rather minor alterations in glycemic control, indicating 
a substantial level of redundancy in expression and signaling.  
The aim of this study was to determine the impact of the combined inactivation of Tbc1d1 and 
Tbc1d4 on glucose metabolism. Therefore, we characterized energy- and substrate 
metabolism of Tbc1d1/Tbc1d4- double-deficient mice. Our results demonstrate that both 
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TBC1D1 and TBC1D4 operate in concert and play essential roles in insulin-stimulated 
glucose uptake and substrate preference in skeletal muscle.  
 
Material & Methods 
Materials – Radiochemicals ([9,10(n)-
3
H]-Palmitic acid; 2-[1,2-
3
H(N)]-Deoxy-D-glucose, 
[1-
14
C]-D-Mannitol and [
14
C]-D-Glucose (U) were purchased from Hartmann Analytic, 
Braunschweig, Germany. Human recombinant insulin Actrapid HM Penfill from Novo 
Nordisk Pharma GmbH (Mainz, Germany) was used throughout the experiments.  
Collagenase (type I) was from Worthington Biochemical Corporation, Lakewood, NJ, USA. 
AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) was purchased from Enzo Life 
Sciences, Lörrach, Germany. Antibodies against TBC1D1 and GLUT4 were described 
previously (10). Antibodies against AKT, pAKT (Ser473), AMPKα, pAMPK (Thr172), and 
PCK2, Glycogen synthase and GSK3α were from Cell Signaling, Danvers, MA, USA. 
Antibodies against PCK1 were from Abcam, Cambridge, UK, Antibodies against TBC1D4 
were from Millipore, Temecula, CA, USA, GAPDH Antibodies were from Ambion, Austin, 
TX, USA. Antibodies against IRAP and GLUT1 were a generous gift from Dr. Susanna 
Keller (University of Virginia, VA, USA) and Dr. Annette Schürmann (German Institute of 
Human Nutrition, Germany), respectively. 
Experimental animals – Recombinant congenic Tbc1d1-deficient C57BL/6J mice (whole-
body D1KO) were described previously (10). Mice with targeted deletion of Tbc1d4 (whole-
body D4KO) were obtained from TIGM (Texas A&M Institute for Genomic Medicine, 
Houston, TX, USA) and backcrossed to the D1KO strain using a microsatellite marker-
assisted (“speed congenics”) selection (25). Hererozygous D1KO/D4KO mice (>97.5% 
congenic with C57BL/6J were then intercrossed to generate the four experimental genotypes: 
Wildtype (WT), D1KO, D4KO, and Tbc1d1/Tbc1d4 double-deficient D1/4KO. Animals 
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were kept in accordance with the NIH guidelines for the care and use of laboratory animals 
and all experiments were approved by the Ethics Committee of the State Ministry of 
Agriculture, Nutrition and Forestry (States of Brandenburg and North Rhine-Westphalia, 
Germany). Three to six mice per cage (Macrolon type III) were housed with ad libitum 
access to food and water at a temperature of 22°C and a 12 h light-dark cycle (lights on at 6 
a.m.). After weaning at the age of 19-21 days, animals received a standard chow with 19% 
(wt/wt) protein (23 cal%), 3.3% fat (8 cal%) and 54.1% carbohydrates (69 cal%) containing 
3.06 kcal/g energy (V153x R/M-H, Ssniff, Soest, Germany). 
Genotyping – Isolation of DNA from mouse tail tips was performed with the InViSorb 
Genomic DNA Kit II (Invitek, Berlin, Germany). Genotyping of mice was performed by 
PCR with three primers for the Tbc1d4 knockout (Fwd: 5’-
AGTAGACTCAGAGTGGTCTTGG-3’, Rev-KO: 5’-GTCTTCCGACTCCATATTTGC-3’, 
Rev-WT: 5’-GCAGCGCATCGCCTTCTATC-3’) and primers for D1KO mice as described 
(10). 
RNA extraction, cDNA synthesis and quantitative real-time PCR – RNA extraction and 
cDNA synthesis was performed as described (10). Real-time PCR was performed with an 
Applied Biosystems 7500 Fast Real-Time PCR-System using TaqMan PCR probes (Applied 
Biosystems, Foster City, CA, USA) for Tbc1d1, Tbc1d4, Slc2a4 and data were normalized to 
Actb according to the ∆Ct method (26).  
Analysis of body weight, body composition– Body weight was measured with an electronic 
scale (Sartorius, Göttingen, Germany), body composition was analyzed with a nuclear 
magnetic resonance spectrometer (Echo MRI, Houston, TX, USA).  
Indirect calorimetry – Animals were placed in individual cages and respiratory quotient (RQ) 
was measured after an adaption phase of 24 h by indirect calorimetry as described (23). Rates 
of oxygen consumption (VO2) and carbon dioxide production (VCO2) were monitored for 
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23 h at 22°C at a flow rate of 30 l/min. Animals had free access to water, and food was 
removed during daytime (6 a.m. – 6 p.m.). Whole body carbohydrate and fat oxidation rates 
(g/min) were calculated using the following equations: carbohydrate oxidation rate = 4.585 × 
VCO2 (l/min) − 3.226 × VO2 (l/min); fat oxidation rate = 1.695 × VO2 (l/min) − 1.701 × 
VCO2 (l/min) (27). 
Tolerance tests – For glucose tolerance tests, sterile glucose (2 g/kg body weight, 20% 
solution) was injected intraperitoneally (i.p.) into fasted (16 h) animals. For insulin- and 
AICAR-tolerance tests, non-fasted mice were injected i.p. either with Insulin (1 IU/kg body 
weight) or AICAR (250 mg/kg body weight), and blood samples were taken at 0, 15, 30, 60 
(i.p. ITT and ATT) and additionally at 120 min (i.p.GTT) from the tail tip. Blood glucose 
was determined with a glucometer (Contour, Bayer, Leverkusen, Germany). Plasma insulin 
was measured with ELISA (Insulin Mouse Ultrasensitive ELISA, DRG, Germany). 
Determination of free fatty acids, triglycerides and glycogen – 30 mg frozen tissue (liver and 
skeletal muscle) was pestled and analyzed using the Triglycerides (TRIGS) GPO-PAP Kit 
(Randox, Crumlin, UK) according to the manufacturer’s guidelines. Muscle homogenates 
were tested negatively for adipocyte contamination (Supplementary Figure 1). Glycogen was 
determined by the amyloglucosidase method (28). Tissue homogenates were incubated with 
30%KOH (wt/vol) at 100°C for 30 minutes, respectively. Subsequently, samples were 
supplemented with acetic acid and assay buffer containing sodium acetate and 
amyloglucosidase and incubated 3 h at 37°C. Glucose was then measured enzymatically by a 
glucose oxidase-based colorimetric detection kit (Glucose liquicolor, Human, Taunusstein, 
Germany) according to the manufacturer’s instructions. 
Analysis of glucose uptake in adipocytes – Primary adipose cells were isolated by 
collagenase digestion of epididymal fat pads from 12-16 week old male mice, and basal and 
insulin-stimulated uptake of [
14
C]glucose was performed as described (29). Briefly, freshly 
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isolated adipose cells (30) were incubated in Krebs-Ringer bicarbonate HEPES buffer, pH 
7.4, 200 nM adenosine containing 5% bovine serum albumin without and without 120 nM 
insulin for 30 min before measurement of  [
14
C]glucose uptake. After 30 min, the cells were 
spun through dinonylphtalate oil (Merck, Darmstadt, Germany) to remove excess label, and 
the cell-associated radioactivity was determined by scintillation measurement. The resulting 
counts were normalized to the lipid weight of the samples (29). Measurements were 
performed in quadruplicate. 
Analysis of glucose uptake and fatty acid oxidation in isolated skeletal muscles – [
3
H]2-
deoxyglucose uptake in intact isolated skeletal muscles was performed as described (10). 
Extensor digitorum longus (EDL) and Soleus muscles were removed from anesthetized (500 
mg/kg Avertin (2,2,2-Tribromoethanol, TBE; i.p. Injection)) mice. Animals were then 
euthanized by heart puncture under anesthesia. Isolated muscles were incubated for 30 min at 
30°C in vials containing pre-oxygenated (95% O2/ 5% CO2) Krebs-Henseleit buffer (KHB) 
containing 5 mM HEPES and supplemented with 5 mM glucose and 15 mM mannitol. All 
incubation steps were conducted under continuous gassing (95% O2/ 5% CO2) at 30°C and 
slight agitation. After recovery, muscles were transferred to new vials and incubated for 
30 min in KHB/ 5 mM HEPES/ 15 mM mannitol/ 5 mM glucose under basal condition or in 
the presence of 120 nM insulin or 2 mM AICAR, respectively, throughout the duration of the 
experiment. Then, muscles were incubated for 10 minutes in in KHB/ 20 mM mannitol under 
basal condition or in the presence of 120 nM insulin or 2 mM AICAR, respectively, before 
being transferred to the radioactive glucose transport incubation. After 20 min incubation in 
the presence of 1 mM [
3
H]2-deoxy-glucose and 19 mM [
14
C]mannitol, muscles were 
immediately frozen in liquid nitrogen and stored at -80°C. Cleared protein lysates were used 
to determine incorporated radioactivity by scintillation counting. The counts from 
[
14
C]mannitol were used to correct for the extracellular space.  
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To assess palmitate oxidation, EDL and Soleus muscles were incubated in pre-gassed KHB 
containing 15 mM mannitol, 5 mM glucose, 3.5% fatty acid-free BSA, [
3
H]palmitate and 
600 µM unlabeled palmitate with or without 2 mM AICAR at 30°C for 2 h. After absorption 
of fatty acids to activated charcoal, fatty acid oxidation was determined by scintillation 
measurement of tritiated water. 
Cell surface photolabeling of GLUT4 – Affinity-photolabeling of glucose transporters using 
the Bio-LC-ATB-BGPA compound was performed as described (31). Following a 4h fasting 
period, mice were anesthetized and EDL and Soleus muscles were removed. Muscles were 
incubated in glass vials in pre-oxygenated KHB buffer containing 0.1% BSA, 2 mM 
Pyruvate and 18 mM Mannitol for 30 minutes at 30°C. After recovery, 400 µM Bio-LC-
ATB-BGPA was added and muscles were incubated with (120 nM) or without insulin at 
18°C for 8 minutes in the dark. After UV irradiation (6 min, 354 nm, 4°C) muscles were 
immediately frozen in liquid nitrogen. Recovery of photochemically biotinylated proteins 
from muscle lysates using streptavidin beads (Pierce, Rockford, IL, USA) was performed as 
described, and total and labeled GLUT4 was  determined by Western Blots analysis. 
SDS-PAGE and Western Blot – Tissues were homogenized (20 mM Tris, 150 mM NaCl, 
1 mM EGTA, 1 mM EDTA, 1% (v/v) Triton-X-100, 1 mM Na3VO4, 1 mM β-
glycerolphosphate, 1 mM NaF, 2.5 mM Na4P2O7 and a proteinase inhibitor and a 
phosphatase inhibitor cocktail (Complete and PhosSTOP, Roche, Mannheim, Germany) and 
centrifuged for 10 min at 16.000 rcf at 4°C. Protein content was determined from the 
supernatant with the BCA Protein Assay Kit (Pierce, Rockford, IL, USA).  Immunoblotting 
and detection was performed with ECL Western blot detection analysis system (GE 
Healthcare, Buckinghamshire, UK) as described (23). 
Statistics – Data are reported as means ± SEM. Significant differences were determined by 
one-way or two-way ANOVA (post-hoc test, Bonferroni multiple comparison test) or paired 
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two-tailed Student’s t-test as indicated in the Figure legends. Values of p<0.05 were 
considered statistically significant. 
 
Results 
Tbc1d1/Tbc1d4-double-deficient mice show only marginal differences in body weight, body 
fat 
We crossbred mice deficient in Tbc1d1 (whole-body D1KO) with conventional Tbc1d4 
knockout animals (whole-body D4KO) to yield Tbc1d1/Tbc1d4 double-deficient (D1/4KO) 
mice on a C57BL/6J background. In all tissues analyzed, the abundance of TBC1D4 was not 
altered in Tbc1d1-deficient mice (Fig. 1A-C and Supplementary Figure 2). Equally, TBC1D1 
protein was not changed in mice deficient in Tbc1d4 (Fig. 1A-C, Supplementary Figure 2). 
Male D1KO, D4KO and D1/4KO mice and wildtype littermates (WT) were raised on a 
standard diet (8% calories from fat), and body weight and body composition were measured 
every 3 weeks until week 21. On a standard diet, D1KO, D4KO and D1/4KO mice showed a 
lower body weight and a tendency towards reduced fat mass whereas lean mass was not 
different compared to WT controls (Fig. 1D-F).  
Tbc1d1/Tbc1d4-double-deficient mice show impaired glucose, insulin and AICAR 
tolerance  
Plasma glucose and insulin levels were determined in standard-diet fed male D1KO, D4KO 
and D1/4KO mice and wild-type littermates. D1KO and D4KO mice showed normal plasma 
glucose and insulin levels in both postprandial and fasted states (Fig. 2A, B). In contrast, 
postprandial glucose levels were decreased in D1/4KO mice (WT vs. D1/4KO: 7.31±0.18 vs. 
6.34±0.24 mmol/l; p<0.01) whereas fasting glucose levels were normal. Moreover, fed and 
fasted plasma triglycerides as well as free fatty acids in plasma were not different between 
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the genotypes, respectively (Supplementary Figure 3).  In order to investigate whole-body 
glycemic control of the animals we performed intraperitoneal tolerance tests for glucose 
(i.p.GTT), insulin (i.p.ITT), and AICAR (i.p.ATT).  D1KO and D4KO mice showed normal 
blood glucose levels, as well as normal plasma insulin levels during the i.p.GTT (Fig. 2C and 
2D). In contrast, D1/4KO mice displayed markedly impaired glucose tolerance while insulin 
levels were normal (Fig. 2C and 2D). Similarly, D1KO and D4KO mice showed normal 
blood glucose levels in response to intraperitoneal injection of insulin (i.p.ITT) while 
D1/4KO mice displayed substantially impaired insulin tolerance (Fig. 2E). Lastly, D4KO 
retained normal blood glucose levels in response to intraperitoneal injection of AICAR 
(i.p.ATT) while both D1KO and D1/4KO mice had significantly impaired AICAR tolerance 
(Fig. 2F). 
Tbc1d1/Tbc1d4 depletion increases fatty acid oxidation in vivo 
We investigated whole-body substrate utilization in standard-diet fed male D1KO, D4KO 
and D1/4KO mice and WT littermates. At the age of 13 weeks, animals were placed in 
metabolic cages and indirect calorimetry was conducted for 24 h. On a standard diet, D1KO, 
D4KO and D1/4KO mice showed a substantial reduction in respiratory quotient (RQ) 
compared to wild-type controls during the dark phase (Fig. 3A, B). Whole-body fat oxidation 
rates were increased substantially whereas whole-body carbohydrate oxidation rate was 
significantly reduced only in D1/4KO mice (Fig. 3C, D).  
Glucose uptake is impaired in skeletal muscle from Tbc1d1/Tbc1d4-double-deficient mice 
In order to determine the specific contribution of TBC1D1 and TBC1D4 to glucose uptake in 
skeletal muscle, EDL and Soleus muscles from 16-week-old male mice were isolated and 
assayed for insulin- and AICAR-stimulated uptake of 2-deoxyglucose as described in the 
methods section. In glycolytic EDL muscle, basal 2-deoxyglucose uptake was not 
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significantly different between the genotypes (Fig. 4A). In contrast, glucose uptake in 
response to insulin was substantially impaired in EDL muscles from D1KO and D1/4KO 
mice whereas glucose uptake in EDL muscle from D4KO mice was normal (Fig. 4A). 
Similarly, AICAR-stimulated uptake of 2-deoxyglucose was markedly decreased in EDL 
muscles from D1KO and D1/4KO mice but not in EDL muscles from D4KO mice (Fig. 4B). 
In oxidative Soleus muscle, basal glucose uptake was also not different between the 
genotypes (Fig. 4C). However, insulin-stimulated glucose uptake was markedly reduced in 
Soleus muscles from D4KO and D1/4KO mice whereas glucose uptake in the Soleus muscle 
from D1KO mice was normal (Fig. 4C). Again, AICAR-stimulated glucose uptake was 
decreased correspondingly (Fig. 4D).  
Glucose uptake is impaired in WAT from Tbc1d1/Tbc1d4-double-deficient mice 
We determined the impact of Tbc1d1/Tbc1d4-deficiency on glucose uptake in isolated white 
adipose cells. Adipose cells from 16week-old male mice were isolated by collagenase 
digestion and assayed for insulin-stimulated uptake of 
14
C-D-glucose as described in the 
methods section.  In basal adipose cells, glucose uptake was not different between the 
genotypes (Fig. 4E). However, insulin-stimulated glucose uptake was markedly reduced in 
adipose cells from D4KO and D1/4KO mice whereas glucose uptake in cells from D1KO 
mice was normal (Fig. 4E).  
Tbc1d1/Tbc1d4-deficiency has no impact on signaling of AKT2 and AMPK 
We next investigated whether insulin or AMPK signaling were impaired in skeletal muscle 
from D1KO, D4KO, and D1/4KO mice. Basal and insulin (120 nM; 60 min) stimulated EDL 
muscle was homogenized, and AKT expression and phosphorylation of AKT
Ser473
 was 
analyzed by Western blot. In addition, basal and AICAR-stimulated (2 mM; 60 min) Soleus 
muscle were homogenized, and both AMPK expression and phosphorylation of AMPK
Thr172 
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were analyzed by Western blot. Quantitative assessment of replicate skeletal muscle samples 
revealed that neither expression nor phosphorylation of AKT or AMPK differed between 
genotypes (Fig. 4F). Moreover, we found no evidence for compensatory changes in 
phosphorylation of TBC1D1 and TBC1D4 (TBC1D1
Ser237
, TBC1D4
Thr588
, PAS 
phosphoylation) in insulin-stimulated skeletal muscle from knockouts (Supplementary Figure 
4)  
Tbc1d1/Tbc1d4-deficiency results in elevated FAO in skeletal muscle 
To determine the role of TBC1D1 and TBC1D4 in lipid utilization in skeletal muscle, EDL 
and Soleus muscles from 16-week-old male mice were isolated and assayed for basal and 
AICAR-stimulated oxidation of palmitate as described in the methods section. In glycolytic 
EDL muscle, basal palmitate oxidation was increased substantially (~2-fold) in mice 
deficient in either Tbc1d1, Tbc1d4 or both (Fig. 5A). In intact isolated EDL muscle from 
control animals, AICAR stimulation led to a >2-fold increase in FAO (Fig. 5A). In contrast, 
in EDL muscle from D1KO, D4KO and D1/4KO mice, the rates of FAO were not further 
increased in response to AICAR (Fig. 5A). In oxidative Soleus muscle, basal palmitate 
oxidation was markedly increased (~1.4-fold) in mice deficient in Tbc1d1 whereas no 
changes in FAO were observed in mice lacking either Tbc1d4 or double-deficient mice (Fig. 
5B). For AICAR-stimulated FAO in Soleus muscle, no significant differences were observed 
between the genotypes (Fig. 5B). The copy numbers of mitochondrial DNA (mtDNA) in 
Gastrocnemius muscle were not different between genotypes (Supplementary Figure 5A). 
However, citric acid synthase (CS) activity was moderately elevated in Gastrocnemius 
muscle from D1KO mice (Supplementary Figure 5B).  
Abundance of GLUT4 is reduced in skeletal muscle and WAT from Tbc1d1/Tbc1d4-
deficient mice  
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In skeletal muscle, the mRNA levels for GLUT4 were not different between the genotypes 
(Supplementary Fig. 6).  To further examine the mechanism for the reduced insulin- and 
AICAR-stimulated glucose uptake in skeletal muscle and adipose cells, tissues from 16-
week-old male mice were homogenized and the abundance of GLUT4 protein was 
determined by Western blot analysis. D1KO mice displayed strongest reduction (~40-50%) 
in GLUT4 content in EDL and Tibialis anterior (TA) muscle, whereas the abundance of 
GLUT4 was reduced by only ~30% in Quadriceps muscle (Fig. 6A, B, E). In D4KO mice, 
GLUT4 was reduced to ~75% in Soleus muscle and to ~60% in WAT (Fig. 6C, F). 
Correspondingly, D1/4KO mice showed reduced GLUT4 content in all tissues analyzed. The 
abundance of the GLUT4-associated aminopeptidase IRAP (32) was also significantly 
reduced in EDL and Soleus muscle from D1/4KO mice (Supplementary Fig. 7).  
RabGAP-deficiency impairs basal retention of GLUT4 in intracellular vesicles 
We investigated alterations in the subcellular distribution of GLUT4 by using bio-LC-ATB-
BGPA, a cell surface impermeant bis-glucose photolabeling reagent (31). Intact isolated EDL 
and soleus muscles from D1KO mice were incubated with bio-LC-ATB-BGPA in the 
absence or presence of insulin as described in methods. After UV irradiation to cross-link the 
photoactivated diazirine group of bio-LC-ATB-BGPA to cell surface-localized glucose 
transporters, photolabeled GLUT4 was recovered from cell membranes by using streptavidin-
agarose and quantified by immunoblotting with GLUT4 antibodies. Compared to the 
wildtype controls, the amount of photolabeled cell surface GLUT4 was significantly reduced 
in insulin-stimulated EDL muscles (Fig. 7A). In contrast, basal levels of photolabeled cell 
surface GLUT4 from Tbc1d1-deficient EDL were not different from controls. In soleus 
muscle from D1KO mice however, the levels of photolabeled GLUT4 was similar in the 
basal and insulin -stimulated states, respectively (Fig. 7B). When the amount of total GLUT4 
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is taken into account, the proportion of GLUT4 at the cell surface is increased in EDL but not 
in soleus muscle from D1KO mice (Fig. 7C, D). Similar changes occur in D4KO mice (24).  
Tbc1d1/Tbc1d4-deficiency reduces glycogen and increases triglyceride levels in the liver.   
We investigated the impact of Tbc1d1/Tbcd4 deficiency on the content of triglycerides and 
glycogen in skeletal muscle and liver from mice fasted for 4 h. Hepatic glycogen levels were 
substantially decreased in D1KO, D4KO and D1/4KO mice when compared to WT controls 
(Fig. 8A). In contrast, fasting glycogen was increased in Quadriceps muscle of D1/4KO mice 
compared to WT controls (Fig. 8B). There was a trend for increased glycogen in 
Gastrocnemius muscle in D1/4KO mice, but the difference was not significant (Fig. 8B). 
Abundance of glycogen synthase (GS) and phosphorylation (Ser
641
) were not significantly 
different between the genotypes in liver and muscle (Supplementary Figure 8). Also, no 
differences in abundance of GSK3α and phosphorylation (Ser
21
) were observed in liver and 
muscle (Supplementary Figure 8). Hepatic triglyceride levels were increased in D1KO, 
D4KO and D1/4KO mice (Fig. 8C) whereas triglycerides in muscle were not changed (Fig. 
8D). Expressions of both forms of the gluconeogenic enzyme phosphoenolpyruvate 
carboxykinase, Pck1 and Pck2, were increased in liver from D1KO, D4KO and D1/4KO 
mice (Fig. 8E, F). 
 
Discussion 
In this study, we investigated the impact of the combined inactivation of Tbc1d1 (D1KO) and 
Tbc1d4 (D4KO) on glucose and lipid metabolism in Tbc1d1/Tbc1d4- double-deficient 
(D1/4KO) mice. Our results demonstrate that both RabGAPs play critical roles in GLUT4 
trafficking, glucose and lipid metabolism in muscle and adipose tissue.  
Page 14 of 42Diabetes
15 
 
On a standard diet, D1/4KO mice showed moderately reduced body weight and a trend 
towards reduced fat mass. Moreover, D1/4KO mice showed a reduced RQ which resulted 
from a substantial increase in whole-body fatty acid oxidation and decreased use of 
carbohydrates as fuel. Both D1KO and D4KO mice displayed a similar reduction in body 
weight and RQ, suggesting that Tbc1d1 and Tbc1d4 may both contribute to energy substrate 
preference in the animals. In a previous study, animals expressing a signaling-deficient 
Tbc1d4-(T642A) mutant (33) also displayed reduced body weight, whereas Tbc1d4 knockout 
mice generated by Nestin-Cre/Lox-mediated deletion of the gene showed no significant 
change in  body weight (14). In contrast, Tbc1d1 deficiency was found to substantially 
reduce body weight and RQ in high-fat diet-fed obese mice, indicating a possible interaction 
of the gene with dietary fat and/or obesity (10).  
Similar to the single knockouts, D1/4KO mice had normal fasting glucose levels. However, 
in contrast to D1KO and D4KO animals, D1/4KO mice displayed markedly impaired 
tolerance to glucose, insulin and AICAR, indicating an important role of both RabGAPs in 
glucose disposal in vivo. Thus, the impact of a single RabGAP knockout on glycemic control, 
i.e. D1KO and D4KO, appears to be largely compensated by the residual RabGAP activity of 
the functioning gene whereas inactivation of both RabGAPs leads to a pronounced 
impairment of glucose disposal. Interestingly, D1KO mice had reduced AICAR tolerance 
compared to D4KO animals, indicating an increased relevance of TBC1D1 in the AICAR 
response. This might reflect tissue specific differences in RabGAP abundance and/or AICAR 
sensitivity of the RabGAPs. The reduced postprandial glucose levels in D1/4KO mice could 
be related to a proposed function of the RabGAPs in insulin secretion (34; 35). However, we 
did not observe genotype-specific differences in circulating insulin levels. 
In mice, Tbc1d1 is predominantly expressed in glycolytic muscle fibers whereas Tbc1d4 is 
expressed more strongly in oxidative muscle and in adipose cells (14; 23). Consistent with 
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the tissue-specific expression profile of both RabGAPs, insulin-stimulated glucose uptake in 
D1KO mice was substantially reduced in intact isolated EDL muscle, but normal in Soleus 
muscle and isolated adipose cells. Conversely, D4KO mice showed severely impaired 
insulin-stimulated glucose uptake in Soleus muscle and adipose cells whereas glucose uptake 
was normal in EDL muscle.  The combined ablation of both RabGAPs in D1/4KO mice 
essentially resulted in elimination of insulin- and AICAR- stimulated glucose uptake in EDL 
and Soleus muscle, and in a substantial reduction of insulin-stimulated glucose uptake in 
adipose cells. However, deletion of one of the RabGAPs (e.g. Tbc1d1 in EDL, Tbc1d4 in 
Soleus and WAT) is sufficient to abolish insulin and AICAR-stimulated glucose uptake 
without any further reduction in glucose transport in these tissues in the double knockout 
mice. In D1KO mice GLUT4 associated glucose transport is clearly deficient in glycolytic 
muscle and yet GTT and ITT responses are normal. This suggests that glycolytic muscle 
types alone are not essential for maintenance of whole animal glucose homoeostasis, possibly 
due to a background maintenance of TBC1D4 activity and normal glucose transport activity 
in non-glycolytic muscle. Consistent with these findings, previous studies of GLUT4-
deficient mice also demonstrated substantial compensation for reduced glucose transport in 
muscle and adipose tissue by altering hepatic fuel metabolism and increasing utilization of 
fatty acids (36). Thus, taken together, Tbc1d1 and Tbc1d4 play an essential role in insulin- 
and AICAR-stimulated glucose uptake in both skeletal muscle and adipose cells, 
respectively.  
The reduced glucose uptake in response to insulin and AICAR was paralleled by 
considerable reduction in GLUT4 abundance in muscle and adipose cells, respectively. 
Because the mRNA levels of GLUT4 were unaltered in the knockout mice, the decrease in 
glucose transporters is likely the result of posttranslational events and may reflect missorting 
of the protein, presumably due to altered function of one or more Rabs downstream of 
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TBC1D1/TBC1D4 (14; 23; 24; 37). Consistent with a defect in protein sorting, the 
abundance of the insulin-regulated aminopeptidase IRAP, a resident protein of GLUT4 
vesicles (38; 39), binding partner of TBC1D4 (40) and potential regulator of GLUT4 sorting 
(41), was also significantly reduced in both EDL and Soleus muscle from D1/4KO mice. 
Previous studies have shown that in adipose cells and skeletal muscle basal glucose transport 
is strongly correlated with the abundance of GLUT4 protein. Deletion of GLUT4 in these 
tissues led to a profound reduction in basal glucose transport whereas overexpression of 
GLUT4 resulted in a substantial increase in basal uptake of glucose into the cells (42-45). In 
contrast, in skeletal muscle and adipose cells from D1KO, D4DO and D1/4KO mice, basal 
glucose transport was normal despite substantially reduced abundance of cellular GLUT4 
protein. Thus, the dissociation of basal glucose transport and GLUT4 abundance mice 
suggests that lack of RabGAPs leads to a redistribution of GLUT4 from intracellular 
compartments to the cell surface in the basal state. We therefore investigated the subcellular 
distribution of GLUT4 by cell surface photolabeling of the protein in EDL and Soleus muscle 
from D1KO mice and compared the surface level with the total GLUT4 level. Consistent 
with the glucose transport data, the amount of basal cell surface GLUT4 in EDL muscle of 
D1KO mice was comparable with wild type despite lower abundance of total GLUT4. Thus, 
in unstimulated D1KO cells, a higher proportion of GLUT4 was present on the cell surface. 
In the insulin stimulated state, both glucose uptake and cell surface GLUT4 were equally 
reduced compared with wild-type, indicating that the fraction of GLUT4 that is present on 
the plasma membrane in insulin-stimulated cells is relatively normal. Thus while it is not 
known at what stage in GLUT4 trafficking TBC1D1 and TBC1D4 participate at the 
molecular level, our findings are consistent with the RabGAPs being involved in intracellular 
retention of GLUT4 vesicles in the basal state (22; 46).  
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Consistent with the reduction in RQ, D1KO, D4KO and D1/4KO mice exhibited elevated 
basal FAO in EDL muscle. In the oxidative Soleus muscle, FAO was only elevated in D1KO 
mice and not further increased by AICAR stimulation. Unexpectedly, Soleus muscle from 
D1/4KO mice did not show increased FAO despite the lack of TBC1D1, indicating that 
additional factors might be involved that modulate lipid oxidation in this type of muscle. In 
contrast, D1KO, D4KO and D1/4KO mice had equally increased levels of FAO in glycolytic 
EDL muscle which also was not further increased by AICAR. Thus, in glycolytic muscle 
inactivation of each RabGAP equally contributes to the elevated FAO. Moreover, elevation 
of FAO is not directly related to impaired glucose uptake as Tbc1d4 knockouts have normal 
glucose uptake but increased FAO in EDL muscle. The mechanism responsible for the 
elevated FAO in glycolytic skeletal muscle of RabGAP-deficient mice remains to be 
clarified. Previously we have shown that knockdown Tbc1d1 in cultured skeletal muscle cells 
also increases fatty acid uptake and oxidation whereas overexpression of the gene has the 
opposite effect (10). However, overexpression of a RabGAP-deficient mutant, Tbc1d1-
R941K, had no effect on fatty acid uptake and oxidation, indicating an involvement of Rab-
GTPases in this process (10). Interestingly, knockout of both Tbc1d1 and Tbc1d4 did not 
exert additive effects on FAO in EDL muscle which suggests that both RabGAPs may 
regulate the same downstream target.  
RabGAP-deficient D1/4KO mice phenocopy adipose- and muscle-specific GLUT4 knockout 
mice (AMGKO) as these animals show substantially reduced glucose uptake in response to 
insulin, and elevated use of lipids as energy source (36). In fact, the reduced abundance of 
GLUT4 at least in part explains the decreased glucose uptake in response to a stimulus. The 
inability to utilize glucose in muscle and adipocytes is associated with elevated hepatic 
trigycerides and reduced hepatic glycogen content, whereas fasting glycogen levels in 
skeletal muscle tend to be increased. While hepatic glycogen levels of AMGKO mice were 
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not reported, conversion of glucose to fatty acids in the liver was substantially increased in 
these animals (36). Consistent with our data, muscle specific GLUT4 knockout mice also 
displayed increased fasting glycogen content in skeletal muscle despite substantially reduced 
glucose uptake (47). A complex counterregulation of increased glycogen synthesis and 
decreased glycogen breakdown was proposed to explain this effect (47). We could not 
confirm a substantial increase in glycogen synthesis in skeletal muscle from fasted D1/4KO 
mice, however, the effect size might be larger in muscle completely lacking GLUT4. Thus, 
the mechanistic basis for the underlying tissue crosstalk remains to be further explored. 
In summary, our results indicate that both RabGAPs play important roles in GLUT4 
trafficking, glucose and lipid metabolism in muscle and adipose cells. So far, of the many 
Rab GTPases previously found to be associated with GLUT4-containing compartments (48; 
49), only Rab8, Rab10 and Rab14 were identified as substrates for both TBC1D1 and 
TBC1D4 in vitro, and furthermore have been implicated to play roles in trafficking of 
GLUT4 in vivo (50-53). Future studies are required to investigate the specific contribution of 
the Rabs to the regulation of metabolic flexibility.   
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Figure legends  
Figure 1: Disruption of Tbc1d1 and Tbc1d4 moderately reduces body weight. A, Western 
Blot of TBC1D1 and TBC1D4 in Tibialis anterior (TA) muscle and white adipose tissue 
(WAT) from Tbc1d1-deficient (D1KO), Tbc1d4-deficient (D4KO) and double-deficient 
(D1/4KO) mice. B, Quantification of TBC1D1 and TBC1D4 protein abundance determined 
by Western Blot analysis in glycolytic EDL (Extensor digitorum longus) muscle and C, 
oxidative Soleus muscle. Data presented as mean ±SEM, n=3-8. D, Body weight development 
of male D1KO, D4KO and D1/4KO. E, Body fat development. F, Lean mass. Data presented 
as mean ±SEM, n=11-22. 
*
p<0.05, 
**
p<0.01, WT vs. D1KO, D4KO, D1/4KO (one-way 
ANOVA). 
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Figure 2: Deficiency in Tbc1d1/Tbc1d4 impairs glucose, insulin and AICAR tolerance. A, 
Blood glucose and B, plasma insulin levels of Tbc1d1-deficient (D1KO), Tbc1d4-deficient 
(D4KO) and double-deficient (D1/4KO) mice in the fed state and after 16h of fasting. Data 
presented as mean ±SEM, n=13-27. 
*
p<0.05, 
**
p<0.01, 
***
p<0.001, fed vs fasted (two-way 
ANOVA) and WT vs. D1/4KO (one-way ANOVA). Male mice aged 12-16 weeks were 
subjected to intraperitoneal (i.p.) tolerance tests for glucose (GTT), insulin (ITT), and AICAR 
(ATT). C, Blood glucose levels of D1KO, D4KO and D1/4KO mice after i.p. injection of 
glucose (2 mg/kg). D, Plasma insulin levels during i.p.GTT. E, Blood glucose levels during 
i.p.ITT (1 IU/ kg). F, Blood glucose levels during i.p.ATT (250 mg/kg). Data presented as 
mean ±SEM, n=8-16. 
*
p<0.05, WT vs. D1KO, D1/4KO  (one-way ANOVA). 
Figure 3: Deletion of Tbc1d1 and Tbc1d4 alters energy substrate preference. Male mice 
aged 12-16 weeks were subjected to indirect calorimetry. A, Respiratory quotient (RQ) of 
D1KO, D4KO and D1/4KO mice. B, Mean respiratory quotient (RQ). C, Whole-body 
carbohydrate oxidation (CHO). D, Whole-body fatty acid oxidation (FAO). Data presented as 
mean ±SEM, n=8-11. 
*
p<0.05, 
**
p<0.01, 
***
p<0.001,WT vs. D1KO, D4KO, D1/4KO (one-
way ANOVA). 
Figure 4: Lack of Tbc1d1 and Tbc1d4 impairs glucose uptake in skeletal muscle and 
adipose cells.  Skeletal muscles and adipose cells from 16-week-old male mice and controls 
were isolated and assayed for glucose uptake. A, Insulin-stimulated [
3
H]-deoxyglucose uptake 
in Extensor digitorum longus (EDL) muscle from D1KO, D4KO and D1/4KO mice (n=9-15). 
B, AICAR-stimulated [
3
H]-deoxyglucose uptake in EDL muscle (n=6-11). C,  Insulin-
stimulated [
3
H]-deoxyglucose uptake in isolated Soleus muscle (n=6-9). D, AICAR-
stimulated [
3
H]-deoxyglucose uptake in isolated Soleus muscle (n=6-11). E, Insulin-
stimulated [
14
C]-D-glucose (U) uptake in isolated adipocytes from epididymal WAT (n=4-6). 
F, Quantification of Western blot analyses of AKT and AMPK phosphorylation in isolated 
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EDL and Soleus muscles after ex vivo insulin and AICAR stimulation, respectively. EDL: Left 
panel, Soleus: Right panel (n=4-6). Data presented as mean ±SEM, 
*
p<0.05, 
**
p<0.01, 
***
p<0.001, basal vs insulin/AICAR (two-way ANOVA), and WT vs. D1KO, D4KO, 
D1/4KO (one-way ANOVA). 
Figure 5: Deletion of Tbc1d1 and Tbc1d4 leads to elevated FAO in skeletal muscle. 
Skeletal muscles from 16-week-old male mice and controls were isolated and assayed for 
fatty acid oxidation as described in methods. A, AICAR-stimulated ex vivo [
3
H]-palmitate 
oxidation in isolated EDL muscle from D1KO, D4KO and D1/4KO mice. B, AICAR-
stimulated ex vivo [
3
H]-palmitate oxidation in isolated Soleus muscle from D1KO, D4KO, 
and D4KO mice. Data presented as mean ±SEM, n=7-8. *p<0.05, 
**
p<0.01, basal vs. AICAR 
(two-way ANOVA) , and WT vs. D1KO, D4KO, D1/4KO (one-way ANOVA). 
Figure 6: Deficiency in Tbc1d1 and Tbc1d4 reduced abundance of GLUT4 in skeletal 
muscle and white adipose tissue. GLUT4 protein abundance was determined by Western 
Blot analysis of tissues from knockout mice and wildtype littermate controls. A, Tibialis 
anterior (TA) muscle. B, Extensor digitorum longus (EDL) muscle. C, Soleus muscle. D, 
Quadriceps muscle. E, Gastrocnemius muscle. F, White adipose tissue. Data presented as 
mean ±SEM, n=5-10.  
*
p<0.05, 
**
p<0.01, 
*** 
p<0.001, WT vs. D1KO, D4KO, D1/4KO (one-
way ANOVA). G, H, Representative Western Blot analysis of TBC1D1, TBC1D4, GLUT1 
and GLUT4 in Extensor digitorum longus (EDL) and Soleus muscle. 
Figure 7: Tbc1d1-deficiency leads to subcellular redistributions of GLUT4.  
Following a 4h fasting period, mice were anesthetized and EDL and Soleus muscles were 
removed. Muscles in the basal and insulin-stimulated states were cell surface labelled with 
impermeant Bio-LC-ATB-BGPA. Biotinylated proteins were recovered from muscle lysates 
using immobilized streptavidin beads and resolved by SDS-PAGE. Total and labelled cell 
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surface GLUT4 were determined by Western Blots analysis. The levels of cell surface 
GLUT4 were then compared without (A, B; EDL and Soleus, respectively; bands show 
recovered biotinylated GLUT4) or with correction for total GLUT4 (C, D; EDL and Soleus, 
respectively; bands show total GLUT4). Data presented as mean ±SEM, n=3-9. 
*
p<0.05, WT 
vs. D1KO (two-tailed unpaired t-test).  
Figure 8: Tbc1d1/Tbc1d4-deficiency reduces glycogen content, increases triglyceride 
levels and abundance of PCK1 and PCK2 in the liver. Tissues from 16-week-old male 
mice were analyzed for content in triglycerides and glycogen, and for protein expression of 
PCK1 and PCK2 by Western Blot. A, Glycogen content in liver (n=18-24). B, Glycogen 
content in Gastrocnemius muscle (n=7). C, Hepatic triglyceride content (n=12-19). D, 
Triglyceride content in Quadriceps muscle (n=7-13). E, F, Abundance of hepatic PCK1 and 
PCK2 expression (n=6). Data presented as mean ±SEM. 
*
p<0.05, 
**
p<0.01, 
***
p<0.001, WT 
vs. D1KO, D4KO, D1/4KO (one-way ANOVA).  
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 Online Supplementary Figure 1: Western blot analysis of Perilipin 1 (PLIN1) protein 
abundance in Gastrocnemius muscle homogenates from wildtype (WT), Tbc1d1-
deficient (D1KO), Tbc1d4-deficient (D4KO) and double-deficient (D1/4KO) mice. Tissue 
homogenates for triglyceride analysis were tested for contamination with adipose cells. 
GAPDH served as loading control. Protein load: 40 µg/lane. WAT, white adipose tissue; M, 
Molecular mass marker. 
  
Page 35 of 42 Diabetes
  
Online Supplementary Figure 2: Abundance of TBC1D1 and TBC1D4 in skeletal muscle 
and white adipose tissue (WAT) from wildtype (WT), Tbc1d1-deficient (D1KO), Tbc1d4-
deficient (D4KO) and double-deficient (D1/4KO) mice. Protein lysates from 
Gastrocnemius muscle (A), TA (Tibialis anterior) muscle (B) and white adipose tissue 
(WAT) (C) of WT, D1KO, D4KO and D1/4KO male mice were prepared and subjected to 
Western Blot analysis of TBC1D1 and TBC1D4. Data presented as mean ±SEM, n=3-6. N.s., 
not statistically significant, WT vs. D1KO, D4KO (one-way ANOVA). 
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Online Supplementary Figure 3: Plasma lipids in wildtype (WT), Tbc1d1-deficient 
(D1KO), Tbc1d4-deficient (D4KO) and double-deficient (D1/4KO) mice. Plasma from 
randomly fed and 6h-fasted 17-23 weeks old male mice on standard diet was analyzed for 
triglyceride content (A) and amount of non-esterified free fatty acids (NEFAs) (B) using the 
Serum Triglyceride Determination Kit (Sigma-Aldrich, Catalog Number TR0100) and the 
NEFA-HR (2) system (Wako Chemicals, Neuss, Germany) according to the manufacturer`s 
instructions, respectively. Data are presented as mean ±SEM, n=6-12. N.s., not statistically 
significant, WT vs. D1KO, D4KO, D1/4KO (one-way ANOVA). 
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 Online Supplementary Figure 4: Analysis of TBC1D1 and TBC1D4 phosphorylation in 
Gastrocnemius muscle from in vivo insulin-stimulated wildtype (WT), Tbc1d1-deficient 
(D1KO) and Tbc1d4-deficient (D4KO) mice.  Mice were i.p. injected with 1 IU/kg Insulin 
and sacrificed by cervical dislocation after 10 minutes. Tissues were removed and 
immediately frozen in liquid nitrogen. Protein lysates from stimulated and unstimulated (i.p. 
injection of 0.9% saline solution) skeletal muscles were prepared and subjected to Western 
Blot analysis of AKT phosphorylation, pSer
588
-TBC1D4, pSer
237
-TBC1D1 and 
‘Phosphorylated AKT substrate’ (PAS). Data presented as mean ±SEM, n=3.  
 
 
 
 
Page 38 of 42Diabetes
 Online Supplementary Figure 5: Mitochondrial copy number and citrate synthase 
activity  in Gastrocnemius muscle from wildtype (WT), Tbc1d1-deficient (D1KO), 
Tbc1d4-deficient (D4KO) and double-deficient (D1/4KO) mice.  A) Mitochondrial copy 
number. The ratio of mtDNA (mt-Nd2) and nuclear DNA (18S) was determined by 
quantitative Realtime PCR using SYBR-Green. B) Citrate synthase activity was analyzed in 
protein lysates using the Citrate Synthase Assay Kit (Sigma-Aldrich, Catalog Number 
CS0720) according to the manufacturer`s instructions. All analyses were performed as 
described in Dokas et al., 2013 (Endocrinology 154:3502–3514). Data presented as mean 
±SEM, n=8. *p<0.05, WT vs. D1KO (one-way ANOVA).  
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Online Supplementary Figure 6: mRNA expression of RabGAP and GLUT4 genes in 
Tibialis anterior (TA) muscle from wildtype (WT), Tbc1d1-deficient (D1KO), Tbc1d4-
deficient (D4KO) and double-deficient (D1/4KO) mice. Expression levels were determined 
by quantitative Realtime PCR analysis using TaqMan PCR probes (Applied Biosystems, 
Foster City, USA) for Tbc1d1 (Mm00497989_m1), Tbc1d4 (Mm00557659_m1), and Slc2a4 
(Mm00436615_m1). Data were normalized to Actb (Mm00607939). Data presented as mean 
±SEM, n=6. 
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 Online Supplementary Figure 7: IRAP protein abundance in skeletal muscle from 
wildtype (WT), Tbc1d1-deficient (D1KO), Tbc1d4-deficient (D4KO) and double-deficient 
(D1/4KO) mice.  Protein lysates from A) Extensor digitorum longus (EDL) and B) Soleus 
muscles were analyzed by Western Blot for IRAP protein. Data presented as mean ±SEM, 
n=6. *p<0.05, WT vs. D4KO (one-way ANOVA).  
 
 
Page 41 of 42 Diabetes
 Online Supplementary Figure 8: Abundance of glycogen synthase (GS) and glycogen 
synthase kinase 3 α (GSK3α), and phosphorylation of GS and GSK3α in liver and 
skeletal muscle from wildtype (WT), Tbc1d1-deficient (D1KO) and Tbc1d4-deficient 
(D4KO) and double-deficient (D1/4KO) mice. Protein lysates from liver and Gastrocnemius 
muscle of WT, D1KO, D4KO and D1/4KO male mice were prepared and subjected to 
Western Blot analysis. A) GS, B) Phospho-GS (Ser
641
), C), GSK3α and D), Phospho-GSK3α 
(Ser
21
). Data presented as mean ±SEM, n=6. 
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